Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma
The use of full-dose intensive regimens of chemotherapy in patients with HIV-associated lymphoma has often resulted in severe toxicity, treatment delay, and reduced subsequent dosing. We conducted a Phase I trial to evaluate the toxicity of the combination of m-BACOD (methotrexate, Bleomycin, doxoru...
Gespeichert in:
| Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1988) 1993-03, Vol.6 (3), p.265-271 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 271 |
|---|---|
| container_issue | 3 |
| container_start_page | 265 |
| container_title | Journal of acquired immune deficiency syndromes (1988) |
| container_volume | 6 |
| creator | WALSH, C WERNZ, J. C LEVINE, A RARICK, M WILLSON, E MELENDEZ, D BONNEM, E THOMPSON, J SHELTON, B |
| description | The use of full-dose intensive regimens of chemotherapy in patients with HIV-associated lymphoma has often resulted in severe toxicity, treatment delay, and reduced subsequent dosing. We conducted a Phase I trial to evaluate the toxicity of the combination of m-BACOD (methotrexate, Bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone) with granulocyte-macrophage colony stimulating factor (GMCSF) in these patients. A total of 17 patients were entered and treated at three dose levels of m-BACOD in combination with a fixed dose of GMCSF. Eight patients received standard dose m-BACOD plus GMCSF without experiencing dose-limiting hematologic toxicity, although significant nonhematologic toxicity was seen. We conclude that it is feasible to treat patients with HIV-associated lymphoma using standard dose m-BACOD plus GMCSF, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_16484667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>5849791</sourcerecordid><originalsourceid>FETCH-LOGICAL-p293t-94eaa4126a3b089b0fe9b7af9e73beac171e4dce703c233d58d11d825cee547b3</originalsourceid><addsrcrecordid>eNpdkE1LxDAYhIsoun78BCGI6KnQfDRpjuv6sQuCHtRreZu-3c2aJrVphf33Flw8eJrDPAwzc5DMGOc0ZazQh8ksK7RINcvzk-Q0xm2W5YVW_Dg5VrLIFGWz5Pt1AxHJigy9BUdCQ9r0br54uSfga7LuwY8umN2ApAXTh24DayQmuOB3JA62HR0M1q9JA2YIPbGeLFcfKcQYjIUBa-KDT5ehXn9afxuJ27XdJrRwnhw14CJe7PUseX98eFss0-eXp9Vi_px2TPMh1QIBBGUSeDVtqbIGdaWg0ah4hWCooihqgyrjZtpd50VNaV2w3CDmQlX8LLn5ze368DViHMrWRoPOgccwxpJKUQgp1QRe_QO3Yez91K2cgqXkXNAJutxDY9ViXXa9baHflfs3J_9670M04JrpPWPjHyYkk5Rq_gNanH7S</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>233663341</pqid></control><display><type>article</type><title>Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma</title><source>Freely Accessible Journals</source><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>WALSH, C ; WERNZ, J. C ; LEVINE, A ; RARICK, M ; WILLSON, E ; MELENDEZ, D ; BONNEM, E ; THOMPSON, J ; SHELTON, B</creator><creatorcontrib>WALSH, C ; WERNZ, J. C ; LEVINE, A ; RARICK, M ; WILLSON, E ; MELENDEZ, D ; BONNEM, E ; THOMPSON, J ; SHELTON, B</creatorcontrib><description>The use of full-dose intensive regimens of chemotherapy in patients with HIV-associated lymphoma has often resulted in severe toxicity, treatment delay, and reduced subsequent dosing. We conducted a Phase I trial to evaluate the toxicity of the combination of m-BACOD (methotrexate, Bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone) with granulocyte-macrophage colony stimulating factor (GMCSF) in these patients. A total of 17 patients were entered and treated at three dose levels of m-BACOD in combination with a fixed dose of GMCSF. Eight patients received standard dose m-BACOD plus GMCSF without experiencing dose-limiting hematologic toxicity, although significant nonhematologic toxicity was seen. We conclude that it is feasible to treat patients with HIV-associated lymphoma using standard dose m-BACOD plus GMCSF, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals.</description><identifier>ISSN: 0894-9255</identifier><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 2331-2289</identifier><identifier>EISSN: 1944-7884</identifier><identifier>PMID: 7680712</identifier><identifier>CODEN: JAISET</identifier><language>eng</language><publisher>New York, NY: Raven Press</publisher><subject><![CDATA[Adult ; AIDS-Related Opportunistic Infections - complications ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Bleomycin - administration & dosage ; Bleomycin - adverse effects ; Cancer ; Chemotherapy ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Dexamethasone - administration & dosage ; Dexamethasone - adverse effects ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Drug therapy ; Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects ; Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use ; HIV ; HIV Core Protein p24 - blood ; Human immunodeficiency virus ; Humans ; Kidney - drug effects ; Leucovorin - administration & dosage ; Leucovorin - adverse effects ; Leukocyte Count - drug effects ; Lung - drug effects ; Lymphoma, AIDS-Related - blood ; Lymphoma, AIDS-Related - drug therapy ; Lymphoma, Non-Hodgkin - blood ; Lymphoma, Non-Hodgkin - drug therapy ; Male ; Medical research ; Medical sciences ; Methotrexate - administration & dosage ; Methotrexate - adverse effects ; Neutropenia - chemically induced ; Pharmacology. Drug treatments ; Remission Induction ; Vincristine - administration & dosage ; Vincristine - adverse effects]]></subject><ispartof>Journal of acquired immune deficiency syndromes (1988), 1993-03, Vol.6 (3), p.265-271</ispartof><rights>1993 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins Mar 1993</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4626119$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7680712$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WALSH, C</creatorcontrib><creatorcontrib>WERNZ, J. C</creatorcontrib><creatorcontrib>LEVINE, A</creatorcontrib><creatorcontrib>RARICK, M</creatorcontrib><creatorcontrib>WILLSON, E</creatorcontrib><creatorcontrib>MELENDEZ, D</creatorcontrib><creatorcontrib>BONNEM, E</creatorcontrib><creatorcontrib>THOMPSON, J</creatorcontrib><creatorcontrib>SHELTON, B</creatorcontrib><title>Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma</title><title>Journal of acquired immune deficiency syndromes (1988)</title><addtitle>J Acquir Immune Defic Syndr (1988)</addtitle><description>The use of full-dose intensive regimens of chemotherapy in patients with HIV-associated lymphoma has often resulted in severe toxicity, treatment delay, and reduced subsequent dosing. We conducted a Phase I trial to evaluate the toxicity of the combination of m-BACOD (methotrexate, Bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone) with granulocyte-macrophage colony stimulating factor (GMCSF) in these patients. A total of 17 patients were entered and treated at three dose levels of m-BACOD in combination with a fixed dose of GMCSF. Eight patients received standard dose m-BACOD plus GMCSF without experiencing dose-limiting hematologic toxicity, although significant nonhematologic toxicity was seen. We conclude that it is feasible to treat patients with HIV-associated lymphoma using standard dose m-BACOD plus GMCSF, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals.</description><subject>Adult</subject><subject>AIDS-Related Opportunistic Infections - complications</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bleomycin - administration & dosage</subject><subject>Bleomycin - adverse effects</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Dexamethasone - administration & dosage</subject><subject>Dexamethasone - adverse effects</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Drug therapy</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</subject><subject>HIV</subject><subject>HIV Core Protein p24 - blood</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Kidney - drug effects</subject><subject>Leucovorin - administration & dosage</subject><subject>Leucovorin - adverse effects</subject><subject>Leukocyte Count - drug effects</subject><subject>Lung - drug effects</subject><subject>Lymphoma, AIDS-Related - blood</subject><subject>Lymphoma, AIDS-Related - drug therapy</subject><subject>Lymphoma, Non-Hodgkin - blood</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Methotrexate - administration & dosage</subject><subject>Methotrexate - adverse effects</subject><subject>Neutropenia - chemically induced</subject><subject>Pharmacology. Drug treatments</subject><subject>Remission Induction</subject><subject>Vincristine - administration & dosage</subject><subject>Vincristine - adverse effects</subject><issn>0894-9255</issn><issn>1525-4135</issn><issn>2331-2289</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1LxDAYhIsoun78BCGI6KnQfDRpjuv6sQuCHtRreZu-3c2aJrVphf33Flw8eJrDPAwzc5DMGOc0ZazQh8ksK7RINcvzk-Q0xm2W5YVW_Dg5VrLIFGWz5Pt1AxHJigy9BUdCQ9r0br54uSfga7LuwY8umN2ApAXTh24DayQmuOB3JA62HR0M1q9JA2YIPbGeLFcfKcQYjIUBa-KDT5ehXn9afxuJ27XdJrRwnhw14CJe7PUseX98eFss0-eXp9Vi_px2TPMh1QIBBGUSeDVtqbIGdaWg0ah4hWCooihqgyrjZtpd50VNaV2w3CDmQlX8LLn5ze368DViHMrWRoPOgccwxpJKUQgp1QRe_QO3Yez91K2cgqXkXNAJutxDY9ViXXa9baHflfs3J_9670M04JrpPWPjHyYkk5Rq_gNanH7S</recordid><startdate>19930301</startdate><enddate>19930301</enddate><creator>WALSH, C</creator><creator>WERNZ, J. C</creator><creator>LEVINE, A</creator><creator>RARICK, M</creator><creator>WILLSON, E</creator><creator>MELENDEZ, D</creator><creator>BONNEM, E</creator><creator>THOMPSON, J</creator><creator>SHELTON, B</creator><general>Raven Press</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>19930301</creationdate><title>Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma</title><author>WALSH, C ; WERNZ, J. C ; LEVINE, A ; RARICK, M ; WILLSON, E ; MELENDEZ, D ; BONNEM, E ; THOMPSON, J ; SHELTON, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p293t-94eaa4126a3b089b0fe9b7af9e73beac171e4dce703c233d58d11d825cee547b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>AIDS-Related Opportunistic Infections - complications</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bleomycin - administration & dosage</topic><topic>Bleomycin - adverse effects</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Dexamethasone - administration & dosage</topic><topic>Dexamethasone - adverse effects</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Drug therapy</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</topic><topic>HIV</topic><topic>HIV Core Protein p24 - blood</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Kidney - drug effects</topic><topic>Leucovorin - administration & dosage</topic><topic>Leucovorin - adverse effects</topic><topic>Leukocyte Count - drug effects</topic><topic>Lung - drug effects</topic><topic>Lymphoma, AIDS-Related - blood</topic><topic>Lymphoma, AIDS-Related - drug therapy</topic><topic>Lymphoma, Non-Hodgkin - blood</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Methotrexate - administration & dosage</topic><topic>Methotrexate - adverse effects</topic><topic>Neutropenia - chemically induced</topic><topic>Pharmacology. Drug treatments</topic><topic>Remission Induction</topic><topic>Vincristine - administration & dosage</topic><topic>Vincristine - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WALSH, C</creatorcontrib><creatorcontrib>WERNZ, J. C</creatorcontrib><creatorcontrib>LEVINE, A</creatorcontrib><creatorcontrib>RARICK, M</creatorcontrib><creatorcontrib>WILLSON, E</creatorcontrib><creatorcontrib>MELENDEZ, D</creatorcontrib><creatorcontrib>BONNEM, E</creatorcontrib><creatorcontrib>THOMPSON, J</creatorcontrib><creatorcontrib>SHELTON, B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of acquired immune deficiency syndromes (1988)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WALSH, C</au><au>WERNZ, J. C</au><au>LEVINE, A</au><au>RARICK, M</au><au>WILLSON, E</au><au>MELENDEZ, D</au><au>BONNEM, E</au><au>THOMPSON, J</au><au>SHELTON, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma</atitle><jtitle>Journal of acquired immune deficiency syndromes (1988)</jtitle><addtitle>J Acquir Immune Defic Syndr (1988)</addtitle><date>1993-03-01</date><risdate>1993</risdate><volume>6</volume><issue>3</issue><spage>265</spage><epage>271</epage><pages>265-271</pages><issn>0894-9255</issn><issn>1525-4135</issn><eissn>2331-2289</eissn><eissn>1944-7884</eissn><coden>JAISET</coden><abstract>The use of full-dose intensive regimens of chemotherapy in patients with HIV-associated lymphoma has often resulted in severe toxicity, treatment delay, and reduced subsequent dosing. We conducted a Phase I trial to evaluate the toxicity of the combination of m-BACOD (methotrexate, Bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone) with granulocyte-macrophage colony stimulating factor (GMCSF) in these patients. A total of 17 patients were entered and treated at three dose levels of m-BACOD in combination with a fixed dose of GMCSF. Eight patients received standard dose m-BACOD plus GMCSF without experiencing dose-limiting hematologic toxicity, although significant nonhematologic toxicity was seen. We conclude that it is feasible to treat patients with HIV-associated lymphoma using standard dose m-BACOD plus GMCSF, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals.</abstract><cop>New York, NY</cop><pub>Raven Press</pub><pmid>7680712</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0894-9255 |
| ispartof | Journal of acquired immune deficiency syndromes (1988), 1993-03, Vol.6 (3), p.265-271 |
| issn | 0894-9255 1525-4135 2331-2289 1944-7884 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16484667 |
| source | Freely Accessible Journals; MEDLINE; Journals@Ovid LWW Legacy Archive; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Adult AIDS-Related Opportunistic Infections - complications Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bleomycin - administration & dosage Bleomycin - adverse effects Cancer Chemotherapy Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Dexamethasone - administration & dosage Dexamethasone - adverse effects Doxorubicin - administration & dosage Doxorubicin - adverse effects Drug therapy Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use HIV HIV Core Protein p24 - blood Human immunodeficiency virus Humans Kidney - drug effects Leucovorin - administration & dosage Leucovorin - adverse effects Leukocyte Count - drug effects Lung - drug effects Lymphoma, AIDS-Related - blood Lymphoma, AIDS-Related - drug therapy Lymphoma, Non-Hodgkin - blood Lymphoma, Non-Hodgkin - drug therapy Male Medical research Medical sciences Methotrexate - administration & dosage Methotrexate - adverse effects Neutropenia - chemically induced Pharmacology. Drug treatments Remission Induction Vincristine - administration & dosage Vincristine - adverse effects |
| title | Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T13%3A04%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20trial%20of%20m-BACOD%20and%20granulocyte%20macrophage%20colony%20stimulating%20factor%20in%20HIV-associated%20non-Hodgkin's%20lymphoma&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1988)&rft.au=WALSH,%20C&rft.date=1993-03-01&rft.volume=6&rft.issue=3&rft.spage=265&rft.epage=271&rft.pages=265-271&rft.issn=0894-9255&rft.eissn=2331-2289&rft.coden=JAISET&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E5849791%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=233663341&rft_id=info:pmid/7680712&rfr_iscdi=true |